VACURG studies of post-prostatectomy survival

Area of Science:

• Urology
• Oncology
• Clinical Trials

Background:

• The Veteran's Administration Cooperative Urological Research Group (VACURG) conducted studies on early-stage prostate cancer treatment.
• Radical prostatectomy and hormonal therapy (diethylstilbestrol - DES) were investigated for their efficacy.

Purpose of the Study:

• To evaluate the impact of radical prostatectomy and diethylstilbestrol (DES) on survival and progression in stage I and II prostate cancer patients.
• To determine if radical prostatectomy offers a significant advantage over observation in managing early-stage prostate cancer.

Main Methods:

• Two VACURG studies involved patients with stage I and II prostate cancer.
• Study 1: Radical prostatectomy followed by randomization to placebo or diethylstilbestrol (DES).
• Study 2: Random assignment to placebo or placebo plus radical prostatectomy.

Main Results:

• Diethylstilbestrol (DES) treatment was associated with worse survival in stage I prostate cancer patients.
• No significant survival difference was observed between DES and placebo groups in stage II patients.
• Radical prostatectomy did not demonstrate a significant advantage in time to progression compared to placebo in stages I and II.
• Tumor size and Gleason histological grade were significant predictors of disease progression.

Conclusions:

• Diethylstilbestrol (DES) may be detrimental for survival in early-stage prostate cancer.
• Radical prostatectomy's benefit in time to progression for early-stage prostate cancer requires further investigation.
• Tumor characteristics like size and Gleason grade are crucial prognostic factors for prostate cancer progression.